- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00936702
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated cancer of unknown primary.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- Evaluate the response rate in patients with previously untreated cancer of unknown primary treated with the combination of carboplatin, paclitaxel, and everolimus.
Secondary
- Assess time to progression, overall survival, duration of response, and time to treatment failure in patients treated with this regimen.
- Determine adverse events of this regimen in these patients.
- Perform descriptive correlative studies to determine response of specific tumor types, identified by the Origin-FFPE test, to this regimen.
OUTLINE: This is a multicenter study.
Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive oral everolimus once daily on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients' tumor tissue samples from the most recent biopsy are analyzed for correlative studies, including gene expression profiling by Origin-FFPE test.
After completion of study therapy, patients are followed up every 3 months until disease progression, and then every 6 months for up to 3 years.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Colorado
-
Fort Collins, Colorado, Verenigde Staten, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Verenigde Staten, 80528
- Front Range Cancer Specialists
-
-
Connecticut
-
Hartford, Connecticut, Verenigde Staten, 06105
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
-
-
Illinois
-
Moline, Illinois, Verenigde Staten, 61265
-
Moline, Illinois, Verenigde Staten, 61265
- Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
-
-
Indiana
-
Elkhart, Indiana, Verenigde Staten, 46515
- Elkhart General Hospital
-
Elkhart, Indiana, Verenigde Staten, 46514-2098
- Elkhart Clinic, LLC
-
Elkhart, Indiana, Verenigde Staten, 46514
- Michiana Hematology-Oncology, PC - Elkhart
-
Indianapolis, Indiana, Verenigde Staten, 46237
- St. Francis Hospital Cancer Care Services
-
Kokomo, Indiana, Verenigde Staten, 46904
- Howard Community Hospital
-
La Porte, Indiana, Verenigde Staten, 46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
Mishawaka, Indiana, Verenigde Staten, 46545-1470
- Michiana Hematology-Oncology, PC - South Bend
-
Mishawaka, Indiana, Verenigde Staten, 46545-1470
- Saint Joseph Regional Medical Center
-
Plymouth, Indiana, Verenigde Staten, 46563
- Michiana Hematology Oncology PC - Plymouth
-
Richmond, Indiana, Verenigde Staten, 47374
- Reid Hospital & Health Care Services
-
South Bend, Indiana, Verenigde Staten, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, Verenigde Staten, 46601
- CCOP - Northern Indiana CR Consortium
-
Westville, Indiana, Verenigde Staten, 46391
- Michiana Hematology Oncology PC - La Porte
-
-
Iowa
-
Ames, Iowa, Verenigde Staten, 50010
- McFarland Clinic, PC
-
Bettendorf, Iowa, Verenigde Staten, 52722
-
Cedar Rapids, Iowa, Verenigde Staten, 52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids, Iowa, Verenigde Staten, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Clive, Iowa, Verenigde Staten, 50325
- Medical Oncology and Hematology Associates - West Des Moines
-
Des Moines, Iowa, Verenigde Staten, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, Verenigde Staten, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, Verenigde Staten, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, Verenigde Staten, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, Verenigde Staten, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Verenigde Staten, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Ottumwa, Iowa, Verenigde Staten, 52501
- McCreery Cancer Center at Ottumwa Regional
-
Sioux City, Iowa, Verenigde Staten, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, Verenigde Staten, 51102
- Mercy Medical Center - Sioux City
-
Sioux City, Iowa, Verenigde Staten, 51104
- St. Luke's Regional Medical Center
-
-
Kansas
-
Chanute, Kansas, Verenigde Staten, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, Verenigde Staten, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, Verenigde Staten, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott, Kansas, Verenigde Staten, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Verenigde Staten, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Verenigde Staten, 67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence, Kansas, Verenigde Staten, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Verenigde Staten, 67901
- Cancer Center of Kansas, PA - Liberal
-
Newton, Kansas, Verenigde Staten, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, Verenigde Staten, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, Verenigde Staten, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, Verenigde Staten, 67401
- Cancer Center of Kansas, PA - Salina
-
Wellington, Kansas, Verenigde Staten, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, Verenigde Staten, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, Verenigde Staten, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, Verenigde Staten, 67214
- CCOP - Wichita
-
Wichita, Kansas, Verenigde Staten, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, Verenigde Staten, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, Verenigde Staten, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Michigan
-
Adrian, Michigan, Verenigde Staten, 49221
- Hickman Cancer Center at Bixby Medical Center
-
Ann Arbor, Michigan, Verenigde Staten, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, Verenigde Staten, 48106
- CCOP - Michigan Cancer Research Consortium
-
Battle Creek, Michigan, Verenigde Staten, 49017
- Battle Creek Health System Cancer Care Center
-
Dearborn, Michigan, Verenigde Staten, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Escanaba, Michigan, Verenigde Staten, 49431
- Green Bay Oncology, Limited - Escanaba
-
Flint, Michigan, Verenigde Staten, 48503
- Hurley Medical Center
-
Flint, Michigan, Verenigde Staten, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Grosse Pointe Woods, Michigan, Verenigde Staten, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Iron Mountain, Michigan, Verenigde Staten, 49801
- Dickinson County Healthcare System
-
Jackson, Michigan, Verenigde Staten, 49201
- Foote Memorial Hospital
-
Lansing, Michigan, Verenigde Staten, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, Verenigde Staten, 48154
- St. Mary Mercy Hospital
-
Monroe, Michigan, Verenigde Staten, 48162
- Community Cancer Center of Monroe
-
Monroe, Michigan, Verenigde Staten, 48162
- Mercy Memorial Hospital - Monroe
-
Muskegon, Michigan, Verenigde Staten, 49444
- Mercy General Health Partners
-
Pontiac, Michigan, Verenigde Staten, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, Verenigde Staten, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Reed City, Michigan, Verenigde Staten, 49677
- Spectrum Health Reed City Hospital
-
Saginaw, Michigan, Verenigde Staten, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Saint Joseph, Michigan, Verenigde Staten, 49085
- Lakeside Cancer Specialists, PLLC
-
Saint Joseph, Michigan, Verenigde Staten, 49085
- Lakeland Regional Cancer Care Center - St. Joseph
-
Traverse City, Michigan, Verenigde Staten, 49684
- Munson Medical Center
-
Warren, Michigan, Verenigde Staten, 48093
- St. John Macomb Hospital
-
-
Minnesota
-
Bemidji, Minnesota, Verenigde Staten, 56601
- MeritCare Bemidji
-
Duluth, Minnesota, Verenigde Staten, 55805
- CCOP - Duluth
-
Duluth, Minnesota, Verenigde Staten, 55805
- Miller - Dwan Medical Center
-
Duluth, Minnesota, Verenigde Staten, 55805-1983
- Essentia Health - Duluth Clinic
-
Rochester, Minnesota, Verenigde Staten, 55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Springfield, Missouri, Verenigde Staten, 65804
- St. John's Regional Health Center
-
Springfield, Missouri, Verenigde Staten, 65807
- Hulston Cancer Center at Cox Medical Center South
-
Springfield, Missouri, Verenigde Staten, 65804
- CCOP - Cancer Research for the Ozarks
-
-
Montana
-
Billings, Montana, Verenigde Staten, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, Verenigde Staten, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, Verenigde Staten, 59107-7000
- Billings Clinic - Downtown
-
Billings, Montana, Verenigde Staten, 59102
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Bozeman, Montana, Verenigde Staten, 59715
- Bozeman Deaconess Cancer Center
-
Butte, Montana, Verenigde Staten, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, Verenigde Staten, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
Helena, Montana, Verenigde Staten, 59601
- St. Peter's Hospital
-
Kalispell, Montana, Verenigde Staten, 59901
- Kalispell Regional Medical Center
-
Missoula, Montana, Verenigde Staten, 59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula, Montana, Verenigde Staten, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
North Dakota
-
Bismarck, North Dakota, Verenigde Staten, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, Verenigde Staten, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, Verenigde Staten, 58502
- St. Alexius Medical Center Cancer Center
-
Fargo, North Dakota, Verenigde Staten, 58122
- CCOP - MeritCare Hospital
-
Fargo, North Dakota, Verenigde Staten, 58102
- MeritCare Broadway
-
-
Ohio
-
Bowling Green, Ohio, Verenigde Staten, 43402
- Wood County Oncology Center
-
Dayton, Ohio, Verenigde Staten, 45405
- Grandview Hospital
-
Dayton, Ohio, Verenigde Staten, 45406
- Good Samaritan Hospital
-
Dayton, Ohio, Verenigde Staten, 45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton, Ohio, Verenigde Staten, 45415
- Samaritan North Cancer Care Center
-
Dayton, Ohio, Verenigde Staten, 45420
- CCOP - Dayton
-
Elyria, Ohio, Verenigde Staten, 44035
- Community Cancer Center
-
Elyria, Ohio, Verenigde Staten, 44035
- Hematology Oncology Center
-
Findlay, Ohio, Verenigde Staten, 45840
- Blanchard Valley Medical Associates
-
Franklin, Ohio, Verenigde Staten, 45005-1066
- Middletown Regional Hospital
-
Greenville, Ohio, Verenigde Staten, 45331
- Wayne Hospital
-
Kettering, Ohio, Verenigde Staten, 45429
- Charles F. Kettering Memorial Hospital
-
Lima, Ohio, Verenigde Staten, 45804
- Lima Memorial Hospital
-
Maumee, Ohio, Verenigde Staten, 43537-1839
- Northwest Ohio Oncology Center
-
Oregon, Ohio, Verenigde Staten, 43616
- St. Charles Mercy Hospital
-
Oregon, Ohio, Verenigde Staten, 43616
- Toledo Clinic - Oregon
-
Sylvania, Ohio, Verenigde Staten, 43560
- Flower Hospital Cancer Center
-
Tiffin, Ohio, Verenigde Staten, 44883
- Mercy Hospital of Tiffin
-
Toledo, Ohio, Verenigde Staten, 43608
- St. Vincent Mercy Medical Center
-
Toledo, Ohio, Verenigde Staten, 43606
- Toledo Hospital
-
Toledo, Ohio, Verenigde Staten, 43614
- Medical University of Ohio Cancer Center
-
Toledo, Ohio, Verenigde Staten, 43617
- CCOP - Toledo Community Hospital
-
Toledo, Ohio, Verenigde Staten, 43623
- Toledo Clinic, Incorporated - Main Clinic
-
Toledo, Ohio, Verenigde Staten, 43623
- St. Anne Mercy Hospital
-
Troy, Ohio, Verenigde Staten, 45373-1300
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Wauseon, Ohio, Verenigde Staten, 43567
- Fulton County Health Center
-
Xenia, Ohio, Verenigde Staten, 45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Virginia
-
Fredericksburg, Virginia, Verenigde Staten, 22401
- Fredericksburg Oncology, Incorporated
-
-
Wisconsin
-
Green Bay, Wisconsin, Verenigde Staten, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Verenigde Staten, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Verenigde Staten, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, Verenigde Staten, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
Manitowoc, Wisconsin, Verenigde Staten, 54221-1450
- Holy Family Memorial Medical Center Cancer Care Center
-
Marinette, Wisconsin, Verenigde Staten, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Oconto Falls, Wisconsin, Verenigde Staten, 54154
- Green Bay Oncology, Limited - Oconto Falls
-
Sheboygan, Wisconsin, Verenigde Staten, 53081
- St. Nicholas Hospital
-
Sturgeon Bay, Wisconsin, Verenigde Staten, 54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria
- Histological confirmation of metastatic adenocarcinoma, poorly differentiated non-small cell carcinoma, or poorly differentiated squamous carcinoma
- Adequate FFPE tissue or re-biopsy planned after registration but prior to treatment
- Measurable disease as defined; for patients having only lesions measuring at least 1 cm to =< 2 cm must use spiral computed tomography (CT) imaging for both pre- and post-treatment tumor assessments; disease that has received prior radiation (performed for palliative reasons) cannot be used for measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Hemoglobin (Hgb) >= 9.0 g/dL
- Absolute neutrophil count (ANC) >= 1,500/uL
- Platelet count >= 100,000/uL
- Total bilirubin =< upper limits of normal (ULN); if liver metastases are present, total bilirubin =< 2 x ULN
- Aspartate aminotransferase (AST) =< 2.5 x ULN; if liver metastases are present, AST =< 5 x ULN
- Creatinine =< 1.25 x ULN; if > 1.25 x ULN calculated creatinine clearance must be >= 60 ml/min
- Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Provide informed written consent
- Willingness to return to NCCTG enrolling institution for follow-up
- Willingness to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study
Exclusion Criteria
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception; note: adequate contraception must be used throughout the trial and for 8 weeks after the last dose of RAD001, by both sexes
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
History of any of the following:
- Known to be human immunodeficiency virus (HIV) positive
- Known prior/current history of hepatitis related to hepatitis B or hepatitis C
Uncontrolled intercurrent illness including, but not limited to the following:
- Ongoing or active infection (acute or chronic)
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Severely impaired lung function
- Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN (note: optimal glycemic control should be achieved before starting trial therapy)
- Liver disease such as cirrhosis or severe hepatic impairment
- Psychiatric illness/social situations that would limit compliance with study requirements
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm =< 4 weeks prior to registration
- Other active malignancy =< 5 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
- Untreated brain metastases; NOTE: patients with treated, stable brain metastases for at least 12 weeks prior to study entry are eligible for enrollment
- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
- Active, bleeding diathesis
- Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
- Currently on enzyme inducing anti-convulsants (EIACs) or other strong inducers or strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
- Current use of warfarin (Coumadin); EXCEPTION: current use of low-molecular weight heparin is allowed
- Known to be HIV positive
- Inoculated with live attenuated vaccines =< 2 weeks prior to registration; note: close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines
- =< 4 weeks from major surgery; note: for this study, diagnostic laparoscopy (without other intervention) and/or biopsies (needle aspirate, core biopsy, open biopsy, etc.) are not considered major surgery
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Treatment (carboplatin, paclitaxel, and everolimus)
Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1.
Patients also receive everolimus PO QD on days 1, 8, and 15.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
IV gegeven
IV gegeven
Gegeven PO
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants With Confirmed Tumor Responses
Tijdsspanne: First 6 Cycles of treatment (an average of 6 months)
|
Confirmed tumor response was defined to be either a complete response (CR) or partial response (PR) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:
|
First 6 Cycles of treatment (an average of 6 months)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Overall Survival
Tijdsspanne: Time from registration to death or last follow-up (up to 3 years)
|
Overall survival was defined as the time from study enrollment to the time of death from any cause or last follow-up.
|
Time from registration to death or last follow-up (up to 3 years)
|
Progression-free Survival
Tijdsspanne: Time from registration to the disease progression or death (up to 3 years)
|
The progression-free survival (PFS) was defined as the time from date of registration to the documentation of disease progression or death as a result of any cause, whichever comes first.
|
Time from registration to the disease progression or death (up to 3 years)
|
Duration of Response
Tijdsspanne: Up to 3 years
|
Duration of response was defined for all evaluable participants who have achieved an objective response as the date at which the participant's objective status is first noted to be either CR or PR to the date progression is documented.
|
Up to 3 years
|
Time to Treatment Failure
Tijdsspanne: Up to 3 years
|
Time to treatment failure was defined to be the time from the date of registration to the date at which the participant is removed from treatment due to progression, adverse events, or refusal.
|
Up to 3 years
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie stoel: Matthew P. Goetz, MD, Mayo Clinic
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata per histologisch type
- Neoplasmata
- Neoplasmata, glandulair en epitheel
- Neoplastische processen
- Neoplasma metastase
- Carcinoom
- Neoplasmata, onbekend primair
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Tubuline-modulatoren
- Antimitotische middelen
- Mitose modulatoren
- Antineoplastische middelen, fytogeen
- Carboplatine
- Paclitaxel
- Everolimus
Andere studie-ID-nummers
- NCCTG-N0871
- NCI-2011-01926 (Register-ID: CTRP (Clinical Trials Reporting System))
- CDR0000643361 (Register-ID: PDQ (Physician Data Query))
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op paclitaxel
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationVoltooidRecidiverend niet-kleincellig longcarcinoom | Stadium IV niet-kleincellige longkankerVerenigde Staten
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActief, niet wervendVergevorderde maagkankerChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Actief, niet wervendRecidiverend mammacarcinoom | Stadium IV Borstkanker AJCC v6 en v7 | Stadium III borstkanker AJCC v7 | Stadium IIIA Borstkanker AJCC v7 | Stadium IIIB Borstkanker AJCC v7 | Stadium IIIC Borstkanker AJCC v7 | Gemetastaseerd borstcarcinoom | Lokaal uitgebreid mammacarcinoomVerenigde Staten
-
Mayo ClinicNational Cancer Institute (NCI)IngetrokkenRecidiverende blaas urotheelcarcinoom | Stadium IV blaas urotheelcarcinoomVerenigde Staten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Actief, niet wervendAnatomische fase I borstkanker AJCC v8 | Anatomisch stadium IA borstkanker AJCC v8 | Anatomisch stadium IB borstkanker AJCC v8 | Anatomische fase II borstkanker AJCC v8 | Anatomisch stadium IIA borstkanker AJCC v8 | Anatomisch stadium IIB borstkanker AJCC v8 | Anatomische fase III borstkanker... en andere voorwaardenVerenigde Staten
-
CTI BioPharmaBeëindigdNSCLCVerenigde Staten, Canada, Bulgarije, Roemenië, Russische Federatie, Oekraïne, Mexico, Argentinië, Hongarije, Polen, Verenigd Koninkrijk
-
Anne NoonanNational Cancer Institute (NCI)WervingStadium IV alvleesklierkanker AJCC v8 | Gemetastaseerd pancreasadenocarcinoomVerenigde Staten
-
Shengjing HospitalWerving
-
CTI BioPharmaBeëindigd
-
Cook Group IncorporatedVoltooidPerifere arteriële ziekte (PAD)Duitsland, Nieuw-Zeeland